HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.

Abstract
Peripheral T-cell lymphomas (PTCLs) are rare lymphomas with mostly poor outcome with current treatment. The addition of etoposide to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and upfront consolidation with autologous stem cell transplantation (auto-SCT) have shown promising results but have never been tested in randomized trials. As a complement to retrospective analyses of clinical trials, we aimed at analyzing prognostic factors and outcome in an unselected, population-based cohort. Through the Swedish Lymphoma Registry, we identified 755 PTCL patients diagnosed during a 10-year period. In addition to International Prognostic Index factors, male gender was associated with an adverse overall survival (OS) (hazard ratio [HR], 1.28; P = .011) and progression-free survival (PFS) (HR, 1.26; P = .014). In an intention-to-treat analysis in 252 nodal PTCL and enteropathy-associated T-cell lymphoma patients (excluding anaplastic lymphoma kinase-positive anaplastic large cell lymphoma), upfront auto-SCT was associated with a superior OS (HR, 0.58; P = .004) and PFS (HR, 0.56; P = .002) compared with patients treated without auto-SCT. The addition of etoposide to CHOP resulted in superior PFS in patients ≤60 years (HR, 0.49; P = .008). This study is the largest population-based PTCL cohort reported so far and provides important information on outcome in PTCL outside the setting of clinical trials.
AuthorsFredrik Ellin, Jenny Landström, Mats Jerkeman, Thomas Relander
JournalBlood (Blood) Vol. 124 Issue 10 Pg. 1570-7 (Sep 04 2014) ISSN: 1528-0020 [Electronic] United States
PMID25006130 (Publication Type: Journal Article)
Copyright© 2014 by The American Society of Hematology.
Chemical References
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone
  • Prednisone
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Cohort Studies
  • Cyclophosphamide (therapeutic use)
  • Doxorubicin (therapeutic use)
  • Etoposide (therapeutic use)
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Lymphoma, T-Cell, Peripheral (diagnosis, epidemiology, therapy)
  • Male
  • Middle Aged
  • Prednisolone (therapeutic use)
  • Prednisone (therapeutic use)
  • Prognosis
  • Registries (statistics & numerical data)
  • Survival Analysis
  • Sweden (epidemiology)
  • Transplantation, Autologous
  • Treatment Outcome
  • Vincristine (therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: